INT83236

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 1999
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 14
Total Number 15
Disease Relevance 8.26
Pain Relevance 2.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (PGR) enzyme binding (PGR) DNA binding (PGR)
cell-cell signaling (PGR) cytoplasm (PGR) signal transduction (PGR)
PGR (Homo sapiens)
Pain Link Frequency Relevance Heat
Oxycodone 17 99.72 Very High Very High Very High
Somatostatin 1 99.44 Very High Very High Very High
narcan 21 99.32 Very High Very High Very High
endometriosis 42 99.06 Very High Very High Very High
analgesia 20 98.04 Very High Very High Very High
Opioid 156 96.96 Very High Very High Very High
pruritus 2 92.24 High High
Morphine 79 88.64 High High
withdrawal 14 86.00 High High
tolerance 12 85.96 High High
Disease Link Frequency Relevance Heat
Cancer 430 100.00 Very High Very High Very High
Apoptosis 24 99.84 Very High Very High Very High
Disease 79 99.52 Very High Very High Very High
Breast Cancer 92 99.32 Very High Very High Very High
Endometriosis 34 99.06 Very High Very High Very High
Constipation 22 96.36 Very High Very High Very High
Reprotox - General 1 23 96.32 Very High Very High Very High
Reprotox - General 3 60 95.68 Very High Very High Very High
Acromegaly 3 95.40 Very High Very High Very High
Genomic Instability 1 94.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CONCLUSIONS: Our study does not support a major contribution of ESR1 and PGR to the pathogenesis of migraine.


Localization (contribution) of PGR
1) Confidence 0.73 Published 2009 Journal Eur. J. Neurol. Section Body Doc Link 19175383 Disease Relevance 0.07 Pain Relevance 0
(ER), progesterone receptor (PgR), proliferation marker (ki-67), tumor suppressor p53, regulator of apoptosis Bcl2, protooncogene cerbB2/HER2neu, epidermal growth factor receptor (EGFR) were assessed according to routine bio- and/or immunohistochemical methods.
Localization (regulator) of PgR associated with cancer and apoptosis
2) Confidence 0.60 Published 2005 Journal J Transl Med Section Body Doc Link PMC1201176 Disease Relevance 0.53 Pain Relevance 0
(ER), progesterone receptor (PgR), proliferation marker (ki-67), tumor suppressor p53, regulator of apoptosis Bcl2, protooncogene cerbB2/HER2neu, epidermal growth factor receptor (EGFR) were assessed according to routine bio- and/or immunohistochemical methods.
Localization (regulator) of progesterone receptor associated with cancer and apoptosis
3) Confidence 0.60 Published 2005 Journal J Transl Med Section Body Doc Link PMC1201176 Disease Relevance 0.53 Pain Relevance 0
Efficacy of PR versus placebo
Localization (Efficacy) of PR
4) Confidence 0.45 Published 2009 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2637543 Disease Relevance 0.29 Pain Relevance 0
ESE are secreted frizzled related protein (SFRP), olfactomedin 1, the progesterone receptor (PR), PR membrane component 1, ER-a, MUC-1, 17bHSD-2, and MMP-11 [14].
Localization (secreted) of PR
5) Confidence 0.29 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1775064 Disease Relevance 0.19 Pain Relevance 0
ESE are secreted frizzled related protein (SFRP), olfactomedin 1, the progesterone receptor (PR), PR membrane component 1, ER-a, MUC-1, 17bHSD-2, and MMP-11 [14].
Localization (secreted) of PR
6) Confidence 0.29 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1775064 Disease Relevance 0.19 Pain Relevance 0
ESE are secreted frizzled related protein (SFRP), olfactomedin 1, the progesterone receptor (PR), PR membrane component 1, ER-a, MUC-1, 17bHSD-2, and MMP-11 [14].
Localization (secreted) of progesterone receptor
7) Confidence 0.29 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1775064 Disease Relevance 0.19 Pain Relevance 0
This premature PR decrease was consistent with an early high progesterone level [79].
Localization (decrease) of PR
8) Confidence 0.08 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0
One study failed to find any PR but reported disease-free survival ?
Neg (failed) Spec (find) Localization (find) of PR associated with disease
9) Confidence 0.07 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2952949 Disease Relevance 0.63 Pain Relevance 0.04
It has been demonstrated that DNMT1, DNMT3A, and DNMT3B are disregulated in endometriosis [48], and it has been suggested that aberrant methylation of HOXA10 and of the progesterone receptor PR-B may be responsible of the disregulation of their expression in endometriosis.
Localization (methylation) of progesterone receptor associated with endometriosis
10) Confidence 0.07 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2837904 Disease Relevance 1.01 Pain Relevance 0.24
Best overall response is PR for 3 patients, SD for 4 patients.
Localization (response) of PR
11) Confidence 0.07 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC2827364 Disease Relevance 1.52 Pain Relevance 0.05
A strong association for rs13281615 was observed for ER+, PR+, and low grade breast tumors [57].
Localization (observed) of PR associated with breast cancer
12) Confidence 0.05 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.75 Pain Relevance 0
Somatostatin and its analogue-prolonged release formulation, lanreotide (Somatuline PR), inhibit the secretion of growth hormone.
Localization (release) of Somatuline PR associated with somatostatin
13) Confidence 0.04 Published 1999 Journal Endocr. J. Section Abstract Doc Link 10426587 Disease Relevance 0.25 Pain Relevance 0.05
A partial response (PR) was defined as a ?
Localization (response) of PR
14) Confidence 0.04 Published 2008 Journal J Transl Med Section Body Doc Link PMC2430193 Disease Relevance 1.24 Pain Relevance 0
Recently there has been increased interest in the use of fixed dose combination of prolonged release (PR) oral oxycodone/naloxone as a method to provide analgesia while preventing opioid-induced constipation.
Localization (release) of PR associated with oxycodone, constipation, narcan, opioid and analgesia
15) Confidence 0.03 Published 2009 Journal Journal of pain research Section Body Doc Link PMC3004622 Disease Relevance 0.87 Pain Relevance 1.85

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox